Switch theme
Sign up to access all valuation multiples
Natco Pharma Ltd is a drug manufacturing company. Natco aims to make specialty medicines accessible to all by manufacturing niche pharmaceutical products backed by its research and development capabilities. While the vast majority of the company's revenue is generated in India, the company looks internationally for growth opportunities. The company maintains a presence in Oncology and Hepatology treatment areas. Natco's active pharmaceutical ingredient segment APIs forms a core part of the company's business. The company operates in two different business segments: pharmaceuticals and agrochemicals. It derives maximum revenue from Pharmaceuticals Segment.
1981
4.8K+
LTM Revenue $510M
LTM EBITDA $247M
$1.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Natco Pharma has a last 12-month revenue (LTM) of $510M and a last 12-month EBITDA of $247M.
In the most recent fiscal year, Natco Pharma achieved revenue of $519M and an EBITDA of $299M.
Natco Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Natco Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $510M | XXX | $519M | XXX | XXX | XXX |
| Gross Profit | $430M | XXX | $438M | XXX | XXX | XXX |
| Gross Margin | 84% | XXX | 84% | XXX | XXX | XXX |
| EBITDA | $247M | XXX | $299M | XXX | XXX | XXX |
| EBITDA Margin | 48% | XXX | 58% | XXX | XXX | XXX |
| EBIT | $225M | XXX | $230M | XXX | XXX | XXX |
| EBIT Margin | 44% | XXX | 44% | XXX | XXX | XXX |
| Net Profit | $212M | XXX | $221M | XXX | XXX | XXX |
| Net Margin | 42% | XXX | 43% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $17.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Natco Pharma's stock price is INR 883 (or $10).
Natco Pharma has current market cap of INR 158B (or $1.9B), and EV of INR 132B (or $1.5B).
See Natco Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.5B | $1.9B | XXX | XXX | XXX | XXX | $1.21 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Natco Pharma has market cap of $1.9B and EV of $1.5B.
Natco Pharma's trades at 3.1x EV/Revenue multiple, and 5.5x EV/EBITDA.
Equity research analysts estimate Natco Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Natco Pharma has a P/E ratio of 8.8x.
See valuation multiples for Natco Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.9B | XXX | $1.9B | XXX | XXX | XXX |
| EV (current) | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| EV/Revenue | 3.0x | XXX | 3.1x | XXX | XXX | XXX |
| EV/EBITDA | 6.3x | XXX | 5.5x | XXX | XXX | XXX |
| EV/EBIT | 6.9x | XXX | 7.1x | XXX | XXX | XXX |
| EV/Gross Profit | 3.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 8.8x | XXX | 9.0x | XXX | XXX | XXX |
| EV/FCF | 10.4x | XXX | 12.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNatco Pharma's last 12 month revenue growth is -13%
Natco Pharma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $44K for the same period.
Natco Pharma's rule of 40 is 42% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Natco Pharma's rule of X is 17% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Natco Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -13% | XXX | -15% | XXX | XXX | XXX |
| EBITDA Margin | 48% | XXX | 55% | XXX | XXX | XXX |
| EBITDA Growth | -29% | XXX | -35% | XXX | XXX | XXX |
| Rule of 40 | 42% | XXX | 42% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 17% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $44K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 40% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Natco Pharma acquired XXX companies to date.
Last acquisition by Natco Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Natco Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Natco Pharma founded? | Natco Pharma was founded in 1981. |
| Where is Natco Pharma headquartered? | Natco Pharma is headquartered in India. |
| How many employees does Natco Pharma have? | As of today, Natco Pharma has 4.8K+ employees. |
| Who is the CEO of Natco Pharma? | Natco Pharma's CEO is Mr. Rajeev Nannapaneni. |
| Is Natco Pharma publicy listed? | Yes, Natco Pharma is a public company listed on BOM. |
| What is the stock symbol of Natco Pharma? | Natco Pharma trades under 524816 ticker. |
| When did Natco Pharma go public? | Natco Pharma went public in 1995. |
| Who are competitors of Natco Pharma? | Similar companies to Natco Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Natco Pharma? | Natco Pharma's current market cap is $1.9B |
| What is the current revenue of Natco Pharma? | Natco Pharma's last 12 months revenue is $510M. |
| What is the current revenue growth of Natco Pharma? | Natco Pharma revenue growth (NTM/LTM) is -13%. |
| What is the current EV/Revenue multiple of Natco Pharma? | Current revenue multiple of Natco Pharma is 3.0x. |
| Is Natco Pharma profitable? | Yes, Natco Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Natco Pharma? | Natco Pharma's last 12 months EBITDA is $247M. |
| What is Natco Pharma's EBITDA margin? | Natco Pharma's last 12 months EBITDA margin is 48%. |
| What is the current EV/EBITDA multiple of Natco Pharma? | Current EBITDA multiple of Natco Pharma is 6.3x. |
| What is the current FCF of Natco Pharma? | Natco Pharma's last 12 months FCF is $148M. |
| What is Natco Pharma's FCF margin? | Natco Pharma's last 12 months FCF margin is 29%. |
| What is the current EV/FCF multiple of Natco Pharma? | Current FCF multiple of Natco Pharma is 10.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
